Momenta Phama (MNTA) Misses Q3 EPS by 8c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Momenta Phama (MNTA) Misses Q3 EPS by 8c, Revenues Miss

AbbVie (ABBV) Announces HUMIRA Global Patent License with Momenta (MNTA)

November 6, 2018 5:05 PM EST

AbbVie (NYSE: ABBV) announced today patent license agreements with Momenta (Nasdaq: MNTA) over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to AbbVie's intellectual... More

Piper Jaffray Starts Momenta Pharmaceuticals (MNTA) at Overweight

November 5, 2018 5:03 AM EST

Piper Jaffray analyst Danielle Brill initiates coverage on Momenta Pharmaceuticals (NASDAQ: MNTA) with a Overweight rating and a price target of $35.00.

For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.

Shares of Momenta Pharmaceuticals closed at $13.66 yesterday.

... More